150 mg and 440 mg multi-dose vial containing powder for concentrate for solution for intravenous infusion. Reconstituted Hertraz concentrate contains 21 mg/mL of trastuzumab, a humanised IgG1 monoclonal antibody expressed in Chinese hamster ovary Cells.
Description:
Hertraz (Trastuzumab) is a monoclonal antibody used to treat breast cancer
Indications:
Metastatic Breast Cancer:
Hertraz is indicated for the treatment of adult patients with HER2 positive metastatic cancer (MBC).
Early Breast Cancer:
Hertraz is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC).
Metastatic Gastric Cancer:
Hertraz in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
Dosage:
Three – Weekly Schedule:
The recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose at threei ntervals is 6 mg/kg body weight, beginning three weeks after the loading units.
Weekly Schedule:
The recommended initial loading dose of trastuzumab is 4 mg/kg body weight. The recommended weekly maintenance dose of trastuzumab is 2 mg/kg body weight, beginning one week after the loading dose.
